Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pathogenesis of neurotropic murine coronavirus is multifactorial

Judith M. Phillips and Susan R. Weiss

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6076, USA

Although coronavirus tropism is most often ascribed to receptor availability, increasing evidence suggests that for the neurotropic strains of the murine coronavirus mouse hepatitis virus (MHV), spike–receptor interactions cannot fully explain neurovirulence. The canonical MHV receptor CEACAM1a and its spike-binding site have been extensively characterized. However, CEACAM1a is poorly expressed in neurons, and the extremely neurotropic MHV strain JHM.SD infects ceacam1a−/− mice and spreads among ceacam1a−/− neurons. Two proposed alternative MHV receptors, CEACAM2 and PSG16, also fail to account for neuronal spread of JHM.SD in the absence of CEACAM1a. It has been reported that JHM.SD has an unusually labile spike protein, enabling it to perform receptor-independent spread (RIS), but it is not clear if the ability to perform RIS is fully responsible for the extremely neurovirulent phenotype. We propose that the extreme neurovirulence of JHM.SD is multifactorial and might include as yet unidentified neuron-specific spread mechanisms.

Introduction

Interruption of virus entry by targeting virus–receptor interactions has long been a goal of vaccination and antibody therapy, and more recently of small-molecule pharmaceutical therapy as well; there are now antiretroviral drugs targeting both the HIV envelope protein and its co-receptor CCR5. The species specificity of coronavirus infections is most often attributed to receptor availability, so the cross-species transmission of severe acute respiratory syndrome (SARS) coronavirus in 2002 focused a great deal of attention on the spike–receptor interaction as a target for therapeutic intervention [1]. However, our experience with neurotropic strains of the murine coronavirus mouse hepatitis virus (MHV, a model widely used for encephalitis and demyelinating disease; Box 1) suggests a paradox: although the spike protein is the most important determinant of neurovirulence [10,11], coronavirus neurotropism cannot be fully explained by receptor use. Two recent studies have confirmed this view. Mice lacking the canonical MHV receptor, CEACAM1a, remain susceptible to viruses expressing the spike protein from the extremely neurotropic JHM.SD (MHV-4) strain of MHV [12]. (JHM.SD is the most neurovirulent isolate [13] of the neurotropic JHM strain, also called MHV-4, which was derived by serial passage through mouse brain [14]). Although JHM.SD spreads efficiently among adjacent ceacam1a−/− neurons, no known alternative receptor is both expressed in neurons and capable of conferring MHV susceptibility to nonpermissive cells [15]. Here we review the known MHV receptor(s) and their spike protein-binding site, as well as the phenomenon of receptor-independent spread (RIS) performed by JHM.SD. Based on current knowledge, we believe that neither receptor use nor RIS can fully explain JHM.SD pathogenesis and hypothesize that the extreme neurotropism displayed by this strain must be multifactorial and include as yet unidentified neuron-specific spread mechanisms. Further studies of neurotropic MHV strains in ceacam1a−/− mice should clarify the mechanism(s) of MHV neurovirulence and guide future attempts to target the spike proteins of encephalitis viruses for therapeutic intervention.

The MHV spike glycoprotein binds the canonical receptor CEACAM1a

The canonical receptor for the murine coronavirus MHV, CEACAM1a, was one of the earliest virus receptors identified. It had long been noted that the SJL/J strain of inbred mice were resistant to MHV, whereas other strains (such as BALB/c) were susceptible. It was demonstrated that MHV binds to a 100–110-kDa protein in BALB/c tissues but not to SJL/J tissue extracts [16]. Inoculation of mice with a partially purified protein extract produced a monoclonal antibody, CC1 [17], which blocked MHV infection of cultured cells [18] and mice [19]. This antibody was used to further purify the receptor [17], and sequencing confirmed that it is a mouse carcinoembryonic antigen (CEA) family member [20] identical to the open reading frame of a transcript, mmCGM1, that was identified by screening a mouse cDNA library with a probe homologous to human CEA [21]. The same screen produced a second transcript, mmCGM2 [22], which was initially misidentified as a splice variant of mmCGM1 [23] and later identified as a different allele for which resistant SJL/J mice are homozygous [24]. (The cDNA library was derived from mice from the outbred CD-1 strain [21] that were apparently heterozygous at the receptor locus.) Although the SJL/J allele acts as an MHV receptor if over-expressed in tissue culture, it fails to bind MHV virions in virus overlay protein blot assays, and the soluble form has fourfold less virus neutralizing activity than the functional allele [25]. This suggests that it is too weak a receptor to function at endogenous levels; in addition, it is not recognized by CC1 [24]. The nomenclature was further complicated by the existence of multiple splice forms [26]; thus, in 1999, the nomenclature of the entire CEA family was revised, with the functional MHV receptor allele designated...
Box 1. Mouse hepatitis virus structural proteins

Coronaviruses are enveloped positive-sense RNA viruses that cause a variety of diseases in humans and animals, most notoriously the outbreak of severe acute respiratory syndrome (SARS) in 2002-2003. Mouse hepatitis virus is a coronavirus used as a model for both liver and CNS disease, facilitating studies of the viral pathogenesis of these organ systems in the natural host. The viral RNA genome is expressed as a set of seven nested mRNAs with a total of 11 open reading frames (ORFs) that encode two large replicase polyproteins (ORF1a and the frameshift product ORF1ab), three nonstructural proteins of unknown function (ORF2a, ORF4 and ORF5a) and six structural proteins: hemagglutinin esterase (HE; ORF 2b), spike (S; ORF5b), envelope (E; ORF5b), membrane (M; ORF6), nucleocapsid (N; ORF7) and internal protein (I; alternative reading frame of ORF7) (Figure 1a). The HE and I proteins are not expressed by all strains of MHV. The structural proteins assemble at the ER-Golgi intermediate compartment (ERGIC), from which they are transported in vesicles to the plasma membrane to be released by exocytosis. The virus particles consist of a positive-sense RNA genome coated with N protein surrounded by an ERGIC-derived lipid bilayer envelope. The five remaining structural proteins are transmembrane proteins embedded in the viral envelope (Figure 1b). M, E, and I have small extracellular domains; HE forms dimers that project from the envelope as small spikes, and the larger, heavily glycosylated S protein forms trimers that project as large spikes or ‘peplomers’ that give coronaviruses their characteristic crown-like appearance by transmission electron microscopy. S protein mediates both attachment to the virus receptor and viral fusion with the cell membrane [2]. S is synthesized as a precursor that is cleaved post-translationally by cellular proteases into N-terminal S1 and C-terminal S2 subunits that remain noncovalently associated [3,4]. The MHV-2 spike protein, which is not cleaved by the producing cell [5,6], is beyond the scope of this article.) The receptor-binding domain of S is associated with S1 and the fusion activity with S2 [7,8]. Although no definitive structure exists, MHV S is believed to be a type I viral fusion protein [9] (like influenza HA or HIV Env), which means that fusion activation should result in presentation of the hydrophobic fusion peptide by a three-stranded coiled-coil motif. Therefore, the fusion-activated conformation of S2 can be detected by aggregation or liposome binding.

ceacam1a and the MHV-resistant SJL/J allele designated ceacam1b (Table 1) [27]. The MHV binding site on CEACAM1a has been extensively characterized. The murine CEA family belongs to the immunoglobulin superfamily and contains two branches: the transmembrane domain-anchored CEACAM proteins and the secreted pregnancy-specific glycoprotein (PSG) proteins. The extracellular portions of these proteins consist of different numbers of variable (V)- (usually N-terminal and designated N) and constant-type (C) immunoglobulin-like domains (divided into A and B subsets and numbered by subset), and many proteins have multiple splice variants [27]. CEACAM1a consists of a V-type N domain followed by either three (A1, B, A2) or one (A2) C-type domains, a transmembrane domain, and a long or short cytoplasmic tail. All four possible splice variants are expressed, generating CEACAM1a-4L, CEACAM1a-4S, CEACAM1a-2L, and CEACAM1a-2S (Figure 1, Table 1) [27]. All four forms support MHV infection in cultured cells [24]. It has been shown that both MHV and CC1 bind to the N domain [31], albeit at slightly different (if overlapping) sites: MHV requires amino acids 34–52 of CEACAM1a, whereas CC1 requires amino acids 1–70 and specifically residues 26–32, 42, and 43 [32]. Independent work identified the contiguous six- amino-acid motif at position 38–43 as crucial for MHV binding [33], and it is noteworthy that CEACAM1b has no homology with CEACAM1a at this sequence (Figure 2). Although the N domain is necessary and sufficient for neutralization and receptor activity [34], a truncated soluble protein containing only the N and A1 domains neutralizes less efficiently than either the two- or four-domain form, which suggests that the fourth Ig-like domain improves MHV binding [25]. The crystal structure of the soluble two-domain protein shows no interaction between the N and A2 domains; however, the critical MHV-binding residues 38–43 are prominently displayed in the N domain.

Table 1. Current and previously published names for mouse hepatitis virus receptors

| New name | Isoform | Old name(s) |
|----------|---------|-------------|
| Ceacam1a | 4L | MHVR(4d), [24]; BgpD [26] |
|          | 4S | mCEA [21]; MHVR [28]; MHVR; [28]; mmCGM1 [21]; mmCGM1a [23]; BgpA [26] |
|          | 2L | BgpG [26] |
|          | 2S | BgpC [26]; MHVR(2d) [24] |
| Ceacam1b | 4L | BgpF [26] |
|          | 4S | BgpE [26] |
|          | 2L | BgpH [26] |
|          | 2S | mmCGM2 [22]; mmCGM1b [23]; BgpB [26] |
| Ceacam2  | 2S | Bgp2C [29]; Bgp2(2d) [29] |
| Psg16    |        | bCEA [30] |
on the CC’ loop of the N domain, which is stabilized in an unusually complex conformation relative to related proteins [35]. The ability of CEACAM1a to bind MHV is thus well understood.

**No known MHV receptor explains the extreme neurotropism of MHV strain JHM**

Although CEACAM1a is sufficient to confer MHV susceptibility to nonpermissive cell lines [28], CEACAM1a expression cannot account for some aspects of MHV tissue tropism. Notably, although some strains of MHV (including A59 and the highly neurotropic JHM) cause central nervous system (CNS) disease, CEACAM1a is poorly expressed in the CNS relative to other MHV target tissues such as the intestine and the liver [15,20]. Furthermore, neurons, which are the predominant CNS cell type infected by both A59 and JHM [11,15], express even lower levels of ceacam1a mRNA than other CNS cell types [15]. However, the ability of A59 to spread among wild-type but not ceacam1a−/− hippocampal neuron cultures implies that neurons do express CEACAM1a protein [15], although the possibility that A59 actually requires CEACAM1a expression by contaminating microglia cannot be ruled out. By contrast, the JHM.SD spike mediates spread even among ceacam1a−/− neurons, although initial infection rates are strikingly lower than for wild-type neurons [15]. At present, the role of CEACAM1a in MHV infection of the CNS is not clear.

One possible explanation for the discrepancy between CEACAM1a expression and MHV infection in neurons is that MHV uses an alternative receptor to infect neurons. This hypothesis is supported by the reduced affinity of the JHM spike for CEACAM1b relative to the A59 spike [25,36,37], which suggests that the receptor-binding
domains of the two proteins differ in a biologically relevant fashion. Two CEA family members have been identified as possible alternative receptors: CEACAM2 and PSG16 (Figure 1). CEACAM2 (previously Bgp2) is similar to CEACAM1a in overall structure, but the MHV-binding loop at amino acids 38–43 has more homology to CEACAM1b (Figure 2). Like CEACAM1b, CEACAM2 can support MHV infection if it is overexpressed in nonpermissive cells [29], but the purified soluble form is less efficient at neutralizing MHV than is CEACAM1a [25]. Studies of the receptor efficiency of the two proteins have been hampered by an inability to control for receptor density, but it is generally believed that CEACAM2 is a less efficient receptor than CEACAM1a [15,29]. At present, it is not clear whether endogenous levels of CEACAM2 can support MHV infection. In addition, ceacam2 mRNA is even more poorly expressed in neurons and glial cells than ceacam1a mRNA is [15]. Together, these data suggest that although CEACAM2 might be an alternative MHV receptor, it is not likely to account for the ability of JHM to spread in ceacam1a−/− neurons.

The other potential MHV receptor, PSG16, is both more promising and more problematic than CEACAM2. Unique among the PSG class, PSG16 is expressed in the CNS [15,30,38] and specifically in neurons [15], which makes it an attractive explanation for the ability of JHM to spread among ceacam1a−/− neurons. Two isoforms of PSG16 have been described (Figure 1) [30,38]. The first, PSG16-4(N1*)C1 (formerly known as bCEA; Table 1), was isolated from mouse brain by screening with a probe homologous to ceacam1a [38]. The second, PSG16-4(N1*)C2, was derived from sequencing of clones from a cDNA library derived from the mouse retina [38] and seems to result from joining of a cryptic splice donor site within the last exon of the −C1 isoform to an additional exon downstream. Both PSG16 isoforms lack the signal sequence and the N-terminal part of the N1 ectodomain relative to other murine PSG proteins (Figure 2). Both, like other PSG proteins, also lack any C-terminal membrane anchor motif. The absence of a membrane anchor does not necessarily preclude receptor activity: C-terminally truncated soluble forms of CEACAM1a were expressed on the cell surface, presumably by binding to membrane-anchored partners, and conferred MHV receptor activity to the expressing cells [34]. The N-terminal truncation is more problematic. Translocation in the absence of a signal sequence, although very uncommon, has been documented, but the PSG16 domain most homologous to the N domain of CEACAM1a is the N1 domain, which is missing the N-terminal MHV-binding site (Figure 2). An attempt to assay the MHV receptor activity of PSG16-4(N1*)C2 by targeting it to the cell surface with the signal sequence and membrane anchor domains of the avian retrovirus receptor TVA did not result in detectable surface expression, although parallel CEACAM1a and CEACAM2 constructs reached the cell surface and supported MHV infection [15]. Currently, it is not clear whether the chimeric PSG16 protein is specifically retained within the secretory pathway or is simply dysfunctional owing to misfolding. A third PSG16 isoform is predicted from analysis of the Psg16 locus and placental expressed sequence tag libraries [39]. This full-length isoform, PSG16-4C1 (Figure 1), contains both a canonical signal sequence and an intact N1 domain and can be amplified from mouse placenta (J.M. Phillips, unpublished observations); however, alignment of the full-length PSG16 with murine CEACAM proteins shows that the MHV-binding motif on the CC’ loop has been entirely deleted (Figure 2). Additional studies are under way to determine whether this novel full-length isoform of PSG16 could be an alternative receptor for MHV.

The labile spike protein of the JHM strain can perform RIS

It is possible that the spike-dependent spread of JHM among ceacam1a−/− neurons relies not on an alternative receptor, but on a phenomenon known as RIS. The most common RIS assay involves overlaying a monolayer of nonpermissive cells with infected permissive cells; for RIS-competent strains of MHV (chiefly JHM.SD and the highly lethal JHM cl-2 isolate [40]), the infected cells fuse with neighboring uninfected cells, which fuse in turn to form large syncytia [41–43]. Neither the A59 strain [42] nor the mildly attenuated JHM.IA [44] performs RIS, and the acid-dependent JHM mutant OBLV60 performs RIS only if the medium is adjusted to the permissive pH [45]. RIS activity depends on the MHV spike glycoprotein but is not blocked by CC1 [45]. A similar assay has been used to study spread from infected microglia to neurons, although it is not clear that the latter truly lack CEACAM1a [15,46]. Fusion also occurs among nonpermissive cells expressing the spike protein alone and is blocked by anti-spike antibodies [45]. Taken together, these data imply that the RIS phenomenon requires only the JHM.SD spike protein.

It is thought that the ability of the JHM.SD spike to mediate RIS is due to the unusual instability displayed by this protein. Both A59 and JHM spike proteins are cleaved during egress into noncovalently associated S1 and S2 subunits (Box 1), and both proteins dissociate if the viruses are incubated at 37°C under mildly alkaline pH, releasing soluble S1 and causing S2 to aggregate on the viral envelope [41,47]; a similar conformational change is observed in response to soluble CEACAM1a and correlates with increased liposome binding [37], which suggests that the conformational change observed at alkaline pH is the same as that responsible for receptor-dependent fusion. However, the JHM.SD spike dissociates more readily than that of A59 or JHM.IA [36,41,44], and mutations in the JHM.SD spike that increase stability decrease the ability to perform RIS [41,44]. In summary, the JHM.SD spike seems to have a more labile S1–S2 interaction than the A59 spike or RIS-inefficient JHM spikes [36], and this hyperlability correlates with RIS.

The extreme neurovirulence of the JHM.SD strain is multifactorial

Although neurons express very little MHV receptor and the highly neurotropic JHM.SD spike is capable of RIS, it is not fully clear that the ability to perform RIS is responsible for the extreme neurovirulence of JHM.SD. JHM.SD forms expanding foci of infected cells in hippocampal neuron cultures from wild-type or ceacam1a−/− mice, which suggests direct cell-to-cell spread, but these neurons do not
obviously form the syncytia [15] that are observed during RIS in cell lines. Several strains of JHM with mutations in S2 have lost the ability to perform RIS and are less neurovirulent than wild-type JHM.SD (J.C. Tsai, unpublished data) [48,49], but many are also deficient in CEACAM1a-dependent fusion [41,50,51], are less able to use CEACAM1b as an alternative receptor [52], or resist neutralization by soluble receptor (i.e. are not triggered by receptor binding) [53] despite wild-type receptor-binding domains, which implies defects in receptor-dependent fusion as well as RIS. The same is true of tissue-culture adapted strains that lack RIS activity due to large deletions in S1 [41]. By contrast, JHM.IA, which has four amino acid substitutions in its spike protein, including one (G310S) that abrogates RIS, has a stable spike and retains full CEACAM1a-dependent fusion activity. Although it is less pathogenic than JHM.SD, JHM1A is still relatively neurovirulent in naive weanling and adult mice [44,54]. On the basis of these conflicting results, we suggest that the extreme neurovirulence of JHM.SD is multifactorial.

Although the extreme virulence of JHM.SD does not seem to depend on RIS alone, the ability to spread among neurons despite minimal CEACAM1a expression in that cell type could be crucial for MHV neurotropism. If so, infection of ceacam1a−/− mice and neurons will be an important tool for investigating the elements of neurovirulence. First, infection of ceacam1a−/− mice and neurons with JHM.IA and RIS-incompetent variants of JHM.SD should clarify whether CEACAM1a-independent spread in neurons is a special case of RIS or a new, neuron-specific phenomenon. If CEACAM1a-independent spread in neurons is distinct from RIS, the next question is whether JHM uses an alternative receptor for interneuronal spread or whether the synaptic environment enables JHM to spread in the absence of any receptor. The former might be identified by screening for neurally expressed proteins that interact with JHM S or confer JHM infection to nonpermissive cells; the latter is more difficult to address, but determination of whether interneuronal spread requires cell-to-cell fusion or release of virus from neurites could suggest further approaches. These experiments should help to elucidate the mechanism of JHM.SD spread in ceacam1a−/− neurons.

Concluding remarks
An increasing body of research suggests that viruses that infect neurons might not use typical virus–receptor interactions for interneuronal spread; for example, both pseudorabies virus (which requires the attachment protein GD for extracellular but not interneuronal spread [55]) and measles virus (which uses a neurotransmitter receptor to spread trans-synaptically in the absence of its canonical receptor [56,57]) use alternative pathways for interneuronal spread. In these cases, drugs that target virus–receptor interactions might protect non-neuronal cells but might not prevent neuron-to-neuron spread of an established infection. The highly neurotropic strains of MHV offer a well-defined virus–receptor system for studying atypical interneuronal spread, and a better understanding of this system might suggest improved therapeutic targets for similarly atypical neuronotropic encephalitis viruses.

Acknowledgments
This work was supported by NIH grant AI-60021 to SRW. JMP was supported in part by NIH grant T32-AI007634-08. We thank Susan Bender for originally creating Figure 1 in Box 1 and Prof. Dr. Wolfgang Zimmermann for assistance with pregnancy-specific glycoprotein nomenclature and for the CEA illustration scheme used in Figure 2. We also thank the members of the Weiss laboratory for critical reading of the manuscript.

References
1. Du, L. et al. (2009) The spike protein of SARS-CoV – a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 229–236
2. Collins, A.R. et al. (1989) Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell–cell fusion. Virology 119, 358–371
3. Frana, M.F. et al. (1985) Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion. J. Virol. 56, 912–920
4. Sturman, L.S. et al. (1985) Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments. J. Virol. 56, 904–911
5. Pu, Y. and Zhang, X. (2008) Mouse hepatitis virus type 2 enters cells through a clathrin-mediated endocytic pathway independent of Eps15. J. Virol. 82, 8112–8123
6. Qiu, Z. et al. (2006) Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J. Virol. 80, 5768–5776
7. Kubo, H. et al. (1994) Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J. Virol. 68, 5403–5410
8. Yoo, D. et al. (1991) The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells. Virology 180, 395
9. Bosch, B.J. et al. (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77, 8801–8811
10. Phillips, J.J. et al. (1999) Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence. J. Virol. 73, 7752–7760
11. Phillips, J.J. et al. (2002) Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system. Virology 301, 109–120
12. Miura, T.A. et al. (2008) The spike glycoprotein of murine coronavirus MHV-JHM mediates receptor-independent infection and spread in the central nervous systems of ceacam1a−/− mice. J. Virol. 82, 755–763
13. Dalziel, R.G. et al. (1986) Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J. Virol. 59, 463–471
14. Bailey, O.T. et al. (1949) A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. II. Pathology. J. Exp. Med. 89, 195–212
15. Bender SJ, et al. (2010) Murine coronavirus receptors are differentially expressed in the central nervous system and play virus strain-dependent roles in neuronal spread. J. Virol. Accepted for Publication.
16. Boyle, J.F. et al. (1987) Genetic resistance to mouse hepatitis virus correlates with absence of virus-binding activity on target tissues. J. Virol. 61, 185–199
17. Williams, R.K. et al. (1990) Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A9 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice. J. Virol. 64, 3817–3823
18. Gagnon, S. et al. (1993) Interaction of mouse hepatitis virus (MHV) spike glycoprotein with receptor glycoprotein MVR is required for infection with an MHV strain that expresses the hemagglutinin-esterase glycoprotein. J. Virol. 69, 889–895
19. Smith, A.L. et al. (1991) Monoclonal antibody to the receptor for murine coronavirus MHV-A59 inhibits viral replication in vivo. J. Infect. Dis. 163, 879–882
20. Williams, R.K. et al. (1991) Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 88, 5533–5536
Characterization of a variant virus selected in rat brains after infection by coronavirus mouse hepatitis virus JHM. J. Virol. 54, 429–435

Krueger, D.K. et al. (2001) Variations in disparate regions of the murine coronavirus spike protein impact the initiation of membrane fusion. J. Virol. 75, 2792–2802

Gallagher, T.M. et al. (1992) Cell receptor-independent infection by a neurotropic murine coronavirus. Virology 191, 517–522

Taguchi, F. et al. (1999) Difference in Bgp-independent fusion activity among mouse hepatitis viruses. Arch. Virol. 144, 2041–2049

Ontiveros, E. et al. (2003) Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycan at residue 310 of the spike glycoprotein. J. Virol. 77, 10260–10267

Nash, T.C. and Buchmeier, M.J. (1996) Spike glycoprotein-mediated fusion in biliary glycoprotein-independent cell-associated spread of mouse hepatitis virus infection. Virology 223, 68–78

Nakagaki, K. and Taguchi, F. (2005) Receptor-independent spread of a highly neurotropic murine coronavirus JHMV strain from initially infected microglial cells in mixed neural cultures. J. Virol. 79, 6101–6110

Sturman, L.S. et al. (1990) Conformational change of the coronavirus peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and virus-induced cell fusion. J. Virol. 64, 3042–3050

Matsumiya, S. et al. (2001) Neurovirulence in mice of soluble receptor-resistant (srr) mutants of mouse hepatitis virus: intensive apoptosis caused by less virulent srr mutant. Arch. Virol. 146, 1643–1654

Peare, B.D. et al. (1994) Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J. Virol. 68, 5483–5495

Tsai, J.C. et al. (2003) Amino acid substitutions within the heptad repeat domain 1 of murine coronavirus spike protein restrict viral antigen spread in the central nervous system. Virology 312, 369–380

Gallagher, T.M. et al. (1991) Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J. Virol. 65, 1916–1928

Matsumiya, S. and Taguchi, F. (2000) Impaired entry of soluble receptor-resistant mutants of mouse hepatitis virus into cells expressing MHVR2 receptor. Virology 273, 80–89

Saeki, K. et al. (1997) Identification of spike protein residues of murine coronavirus responsible for receptor-binding activity by use of soluble receptor-resistant mutants. J. Virol. 71, 9024–9031

MacNamara, K.C. et al. (2005) Contributions of the viral genetic background and a single amino acid substitution in an immunodominant CD8+ T-cell epitope to murine coronavirus neurovirulence. J. Virol. 79, 9108–9118

Feierbach, B. et al. (2007) In vitro analysis of transneuronal spread of an alphaherpesvirus infection in peripheral nervous system neurons. J. Virol. 81, 6846–6857

Lawrence, D.M. et al. (2000) Measles virus spread between neurons requires cell contact but not CD46 expression, syncytium formation, or extracellular virus production. J. Virol. 74, 1908–1918

Makhortova, N.R. et al. (2007) Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology 362, 235–244

Bender, S.J. and Weiss, S.R. (2010) Pathogenesis of murine coronavirus in the central nervous system. J. Neuroimmune Pharmacol 5, 336–354